

# Market Announcement

15 July 2025

---

## Lumos Diagnostics Holdings Limited (ASX: LDX) – Suspension from Quotation

The securities of Lumos Diagnostics Holdings Limited ('LDX') will be suspended from quotation immediately under Listing Rule 17.2 at the request of LDX, pending the release of an announcement by LDX.

Unless ASX decides otherwise, the securities will remain suspended until the earlier of:

- the end of the period stated in LDX's request for voluntary suspension; or
- the release of the announcement to the market.

LDX's request for voluntary suspension is attached below for the information of the market.

### Issued by

ASX Compliance

15 July 2025

Yulia Gurdina  
Senior Adviser, Listings Compliance (Sydney)  
ASX Compliance Pty Limited  
20 Bridge Street  
Sydney NSW 2000

**By email only:** [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

Dear Yulia,

**REQUEST FOR VOLUNTARY SUSPENSION**

Lumos Diagnostics Holdings Limited (ASX: **LDX**) (the **Company**) requests an immediate suspension of the Company's securities (ASX: LDX) quoted on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.2.

The voluntary suspension is requested pending an announcement by the Company to the market in relation to strategic material agreements (**stated purpose**).

In accordance with ASX Listing Rule 17.2, the Company provides the following information in relation to the request:

1. The voluntary suspension is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated purpose.
2. The Company requests that the voluntary suspension remains in place until the earlier of commencement of normal trading on Wednesday, 16 July 2025, or when the announcements regarding the stated purpose are released to the market.
3. The Company expects to make the announcements to the market before the commencement of normal trading on Wednesday, 16 July 2025.
4. The Company is not aware of any reason why the voluntary suspension should not be granted or of any further information necessary to inform the market about the voluntary suspension.

Please contact me if you require any further information concerning this matter.

Yours sincerely,



Tracy Weimar  
Company Secretary  
**Lumos Diagnostics Holdings Limited**